Active clinical trials for "Chordoma"

This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of high-dose chemotherapy. PURPOSE: Phase I trial to study the effectiveness of amifostine in protecting from the side effects of peripheral stem cell transplantation in treating patients who have high-risk or relapsed solid tumors.

QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.

Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is to see if combining the images from the FMISO-PET scan and the CT and MRI scans in radiation treatment planning changes the size and location of the area that will receive radiation treatment when compared to planning the radiation treatment with CT and MRI scans alone.

This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma. For the recurrent population, those patients that do not require immediate surgical resection will be eligible. Patients will be treated with 4 cycles, followed by surgical resection if possible. If indicated, surgery may take place prior to the completion of 4 cycles.

For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high affinity, which also showed broad antitumor activity against EGFR and so on. Thus this multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the efficacy and safety of anlotinib versus imatinib on advanced chordoma.

TRIAL SUMMARY Researchers at the National Cancer Institute (NCI) are now enrolling patients in a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma. Chordoma patients with inoperable or residual tumor who do not have metastases and are planning to be treated with definitive (>70Gy) radiation are eligible to participate. Patients will initially be randomized to receive radiation plus the vaccine or radiation plus a blinded placebo. Those randomized to receive radiation plus placebo will have the option to receive vaccine if their tumor grows while on the study. The study will compare the outcomes of patients treated with radiation with and without the vaccine to determine whether the vaccine can increase the chances of shrinking the tumor and/or preventing further tumor growth. WHY THIS TRIAL IS BEING DONE The primary treatment options for chordoma currently consist of surgery and high dose radiation. Radiation has been shown to improve patient outcomes following surgery. Radiation is also sometimes used instead of surgery when surgery would carry unacceptable risks. The chance of tumor growth after radiation is significantly higher for patients who have residual tumor than for those whose tumor is completely removed. Unfortunately for patients with a tumor that cannot be completely removed, there tends to be a short time until the tumor grows back and eventually causes death. For this reason, our team at the NCI seeks to identify a therapy that can reduce the risk of recurrence and improve survival after radiation for patients who have residual tumor. One approach we are pursuing is treating patients with a therapeutic vaccine that is intended to stimulate the immune system to fight cancer cells that express the brachyury protein. Brachyury is present at very high levels in nearly all chordomas but is not present in the vast majority of normal tissues, making it a promising target for immune therapy. Research in other cancers suggests that radiation in combination with immune therapy can provide powerful antitumor effects. We have recently completed a phase 1 clinical trial of a therapeutic vaccine targeting brachyury called GI-6301 in which 11 chordoma patients participated. Through that phase I trial, we learned that this vaccine can be given safely without serious adverse reactions. In that study, the vaccine was also capable of inducing immune responses against brachyury and one patient had his tumor shrink more than 30% while on study. Some other patients (7 of 10 evaluable) also had stable disease for more than 5 months while on study. However, these clinical findings are not definitive and further clinical testing is required to determine the benefit of this vaccine in chordoma. To that end, we have designed a larger phase 2 clinical trial intended to determine if this vaccine, when given in combination with radiation, improves outcomes for patients with chordoma compared to those who only have radiation. WHO CAN PARTICIPATE We have designed this trial for patients who have residual tumor remaining after surgery, who are unable to have surgery, or who have a local recurrence following previous treatment. To be eligible for enrollment on this study, patients must: Have a confirmed diagnosis of chordoma Have only localized tumor (no metastases) Be able to receive at least 70 Gy of radiation to their localized tumor Be willing to travel to Bethesda, MD for treatment and follow-up visits HOW THE TRIAL WILL WORK The trial is taking place at the National Institutes of Health Clinical Center in Bethesda, MD. The NCI will pay for transportation costs (including airfare) and a portion of lodging costs for patients after enrollment in this study. The process of participating in the trial is as follows: Patients travel to NIH to receive injections of the vaccine (or placebo) every other week for three doses prior to starting radiation (approximately 4 weeks) Patients then complete their radiation treatment with their home radiation oncologist (typically over a 1-2 month timespan) Following completion of radiation treatment plan, patients travel back to NIH to resume vaccine (or placebo) injections every 2 weeks until 6 total doses have been given (3 doses after radiation, another 4 weeks) At that point, doses spread out to every 4 weeks for 4 doses, and then 1 dose every 3 months until disease progression. Between all doses of vaccine, patients may return home and travel back for the next visit. There is no requirement to stay locally in Bethesda at any point in the study outside of clinic visits and dosing days. Repeat imaging studies will be performed about 3 months after completion of radiatio...

This study is a prospective randomised clinical phase III trial. The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the local-progression free survival (LPFS).

The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on cancer and analyze possible side effects.